Nanobodies are tiny antibody fragments, roughly one-tenth the size of a conventional antibody, that can bind to targets in the body with remarkable precision. Weighing just 12 to 15 kilodaltons, they are the smallest naturally derived antibody fragments known, and their compact structure gives them unique advantages in medicine, diagnostics, and research that full-sized antibodies simply can’t match.
Where Nanobodies Come From
Nanobodies exist because of a quirk of camelid biology. Camels, llamas, and alpacas naturally produce a special class of antibodies that are missing an entire structural component. Normal antibodies in humans and most mammals are built from two heavy protein chains and two light protein chains, all locked together in a Y shape. Camelids produce these conventional antibodies too, but they also make a second type composed of heavy chains only, with no light chains at all.
Researchers at the Vrije Universiteit Brussel in Belgium discovered these heavy-chain-only antibodies while other labs were busy trying to engineer smaller antibody fragments in the lab. The discovery was somewhat serendipitous, but its significance was recognized immediately. The antigen-binding tip of each heavy-chain-only antibody is a single small domain, and when isolated, that domain is what we call a nanobody (also known as a VHH). Even on its own, it retains the full binding strength of the original antibody.
How They Differ From Conventional Antibodies
A standard human antibody (IgG) is a large, complex molecule weighing about 150 kilodaltons. A nanobody weighs roughly 12 to 15 kilodaltons and measures about 2.5 nanometers tall by 1 nanometer wide. That size difference has practical consequences at every level, from how well the molecule penetrates tissue to how cheaply it can be manufactured.
Conventional antibodies bind their targets using a flat or slightly concave surface formed by loops on two separate protein domains working together. Nanobodies manage the same job with a single domain, compensating with an unusually long and flexible binding loop called CDR3. This extended loop can snake into narrow grooves, enzyme active sites, and hidden pockets on proteins that a bulkier conventional antibody would never reach. Researchers describe these hard-to-access spots as “cryptic epitopes,” and nanobodies are one of the few tools that can reliably target them.
Key Advantages of Nanobodies
Their small size is only the starting point. Nanobodies are also unusually tough. They resist changes in pH and temperature that would unfold and destroy a conventional antibody fragment, making them easier to store and ship without cold chains in some formulations. They also trigger minimal immune reactions when administered to humans, partly because they can be “humanized” relatively easily during engineering.
Because nanobodies are single-domain proteins with no complex folding between separate chains, they can be produced in bacteria like E. coli or in yeast. Conventional therapeutic antibodies typically require expensive mammalian cell cultures. Bacterial production is faster, simpler, and significantly cheaper, which opens the door to scaling up manufacturing for widespread use. Their genes are also easy to manipulate, so researchers can fuse multiple nanobodies together or attach them to drugs, imaging dyes, or nanoparticles with relatively straightforward genetic engineering.
Tissue penetration is another major advantage. Full-sized antibodies struggle to move deeply into solid tumors or cross tightly packed tissue barriers. Nanobodies, being so much smaller, diffuse more readily into these spaces and distribute more evenly once they get there.
Approved Nanobody Drugs
The first nanobody-based drug to reach patients was caplacizumab, approved in 2018 for a rare and dangerous blood-clotting disorder called immune thrombotic thrombocytopenic purpura. It works by blocking a protein involved in abnormal clot formation in small blood vessels. Since then, several more nanobody-derived therapies have gained approval in different countries.
Envafolimab, a nanobody fused to an antibody backbone fragment, is approved as an injectable treatment for certain solid tumors including soft tissue sarcomas and biliary tract cancer. It targets the same immune checkpoint (PD-L1) that several conventional antibody drugs target, but it can be given as a subcutaneous injection rather than an intravenous infusion. Ozoralizumab, approved in Japan, treats rheumatoid arthritis that hasn’t responded adequately to other therapies by neutralizing a key inflammatory signaling molecule (TNF-alpha). And ciltacabtagene autoleucel (marketed as Carvykti) is an FDA-approved CAR-T cell therapy for advanced multiple myeloma that uses nanobodies on the surface of engineered immune cells to recognize cancer cells.
Nanobodies in Imaging and Research
Outside of drug development, nanobodies have become essential tools in medical imaging and laboratory research. For diagnostic imaging, nanobodies can be labeled with radioactive tracers and used in PET or SPECT scans to visualize tumors or inflammation in the body. Their rapid tissue penetration and fast clearance from the bloodstream produce high-contrast images relatively soon after injection, which is a practical advantage over labeled full-sized antibodies that linger in circulation for days.
In ultrasound imaging, nanobodies have been attached to microbubbles and nanobubbles to highlight blood vessels feeding tumors. In surgical settings, fluorescent-dye-labeled nanobodies are being explored for real-time fluorescence-guided surgery, helping surgeons see tumor margins during an operation.
In the research lab, nanobodies have become a go-to tool for super-resolution microscopy, the techniques that allow scientists to see structures smaller than the diffraction limit of light. Because nanobodies are about ten times smaller than conventional antibodies, they get much closer to the protein they’re labeling. This reduces the “linkage error,” the gap between where the label sits and where the actual target is, producing sharper, more accurate images. Nanobodies have been used with techniques like STED microscopy and STORM to visualize intracellular structures with extraordinary detail. In one striking application, a nanobody fused to a fluorescent protein was used to watch the real-time reshaping of structural proteins in a living mouse brain.
Engineering Multi-Target Nanobodies
One of the most active areas of nanobody development involves linking two or three nanobodies together so a single molecule can grab multiple targets at once. This is particularly valuable in cancer treatment, where tumors often escape single-target therapies by losing the targeted protein from their surface.
Bispecific nanobody constructs have been built to simultaneously recognize two different markers on cancer cells, or to grab a cancer cell with one end and an immune cell with the other, physically bridging them together to trigger killing. Trispecific constructs go further. One experimental CAR-T therapy called LCAR-AIO uses engineered immune cells armed with nanobodies targeting three different proteins (CD19, CD20, and CD22) found on blood cancers, making it much harder for tumor cells to escape by downregulating any single target. A similar approach in acute myeloid leukemia targets three different surface markers to address the genetic diversity within a single patient’s tumor.
The single-domain structure of nanobodies makes these multi-target designs more practical than doing the same thing with conventional antibody fragments. When you link two conventional fragments together, their paired chains can mismatch and misfold. Nanobodies, having just one chain each, avoid this problem entirely. Their small gene size also means you can pack instructions for multiple nanobodies into a single viral delivery vector without running out of space.
The Short Half-Life Problem
The small size that gives nanobodies their advantages also creates their biggest limitation. At 12 to 15 kilodaltons, a nanobody falls well below the kidney’s filtration threshold (roughly 60 kilodaltons). This means nanobodies injected into the bloodstream are filtered out by the kidneys and excreted within hours, far too quickly for many therapeutic applications that need the drug circulating for days or weeks.
Researchers have developed several workarounds. The most common is attaching an extra nanobody that grabs onto albumin, the most abundant protein in blood. This lets the therapeutic nanobody “piggyback” on albumin molecules as they circulate, effectively borrowing albumin’s long natural half-life of about three weeks. Another approach fuses the nanobody to an Fc fragment, the tail portion of a conventional antibody, which also extends circulation time but adds bulk. The albumin-binding strategy is generally preferred when keeping the molecule small matters, such as for solid tumor penetration.
For imaging applications, the rapid clearance is actually an advantage. The nanobody binds its target in tissue, while unbound nanobody washes out through the kidneys quickly, producing a clean, high-contrast image in a fraction of the time needed with conventional antibody-based tracers.